The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs

• Published in: European journal of pharmacology Vol. 275; no. 3; pp. 259 - 266
• Main Authors: Seki, Yukio, Suzuki, Yoshio, Baskaya, Mustafa K., Kano, Takahisa, Saito, Kiyoshi, Takayasu, Masakazu, Shibuya, Masato, Sugita, Kenichiro
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 14.03.1995; Elsevier
• Subjects: Anesthesia; Animals; Biological and medical sciences; Blood flow, vertebral artery; Cerebral Arteries - drug effects; Cerebral Arteries - physiology; Cerebral artery, canine; Cerebrovascular Circulation - drug effects; Cyclic AMP - cerebrospinal fluid; Dogs; Female; Fundamental and applied biological sciences. Psychology; Hemodynamics. Rheology; Male; Neuropeptides - pharmacology; PACAP (pituitary adenylate cyclase-activating polypeptide); Pituitary Adenylate Cyclase-Activating Polypeptide; Vasoactive Intestinal Peptide - pharmacology; Vasodilation; Vasodilation - drug effects; Vertebral Artery - drug effects; Vertebral Artery - physiology; Vertebrates: cardiovascular system; VIP (vasoactive intestinal peptide); VIP (vasoactive intestinal peptide); Cerebral artery, canine; PACAP (pituitary adenylate cyclase-activating polypeptide); Blood flow, vertebral artery; Vasodilation; Fissipedia; Carnivora; Peptide hormone; Neuropeptide; Cerebral artery; Biological activity; Vertebrata; Pituitary hormone; Vasomotricity; Gastrointestinal hormone; Mammalia; Brain (invertebrata); Blood vessel; Hemodynamics; Mechanism of action; VIP; Dog; Pituitary adenylate cyclase activating peptide
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/0014-2999(95)00011-9

We investigated and compared the effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) on cerebral circulation in anesthetized dogs. The intracisternal administration of PACAP-27, PACAP-38, and VIP dilated canine cerebral arteries in a dose-dependent manner. A 10 nmol dose of PACAP-27, PACAP-38, and VIP dilated the basilar artery by 23 ± 3, 27 ± 3 and 30 ± 3%, respectively. Rostrally located arteries tended to be more responsive to PACAP-27. Pretreatment with N G-monomethyl- l-arginine did not affect PACAP-27-induced vasodilation. Vertebral artery blood flow was also affected by intra-arterial injection of these peptides in a dose-dependent manner. A 100 pmol dose of PACAP-27, PACAP-38, and VIP increased the vertebral artery blood flow by 42 ± 10, 29 ± 4, and 62 ± 11%, respectively. The VIP receptor antagonist, [Lys 1,Pro 2,5,Arg 3,4,Tyr 6]VIP, inhibited both the VIP- and PACAP-38-induced increase in vertebral artery blood flow. These findings suggest that PACAP plays a role in the regulation of cerebral circulation.